US judge lets CagriSema investor fraud claims against Novo Nordisk proceed
Judge Robert Kirsch kept the REDEFINE-1 flexible-dosing allegations alive but dismissed claims that Novo's 25% weight-loss expectation was misleading, calling it aspirational.
DO
By Daniel Okafor · Regulatory Correspondent
Jul 29 03:00 ETSource: pharmaphorum
The wire
- 01The class action covers investors who bought Novo Nordisk stock between November 2022 and December 2024, when REDEFINE-1 showed 20.4% weight loss at 68 weeks and shares fell nearly 18%.
- 02Central claim: then-development head Martin Holst Lange allegedly concealed that flexible dosing let patients adjust CagriSema, with only 57% reaching the top dose, implying a tolerability issue.
- 03Novo filed CagriSema for obesity in the US last December with a decision due in coming months, after REDEFINE-4 showed it less effective than Lilly's Zepbound.
From the source
Read at pharmaphorum.comUS judge says Novo Nordisk must face lawsuit over CagriSema
A US judge has ordered that Novo Nordisk must face some allegations in court that it defrauded investors by making misleading comments about a trial of its obesity drug CagriSema.